Treatment of patients with cirrhosis and ascites

Seminars in Liver Disease

Volumn 17, Issue 3, 1997, Pages 249-260

  Runyon, Bruce A ^a  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ascites; Cirrhosis; Treatment

Indexed keywords

AMILORIDE; BUMETANIDE; DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE; TORASEMIDE; TRIAMTERENE;

ASCITES; BED REST; DIET THERAPY; DIURESIS; HOSPICE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; OUTPATIENT; PARACENTESIS; PERITONEUM VEIN SHUNT; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; REVIEW; SODIUM BALANCE; SODIUM INTAKE; SODIUM RESTRICTION; TREATMENT PLANNING; URINALYSIS;

EID: 0030931711     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007202     Document Type: Review

References (72)

1. Shiffman ML, Jeffers L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: a conference sponsored by the National Digestive Diseases Advisory Board. Hepatology 22:1591-7, 1995.
2. Kodali VP, Gordon SC, Silverman AL, McCray DG. Cryptogenic liver disease in the United States: further evidence for non-A, Non-B, and non-C hepatitis Am J Gastroenterol 89:1836-9, 1994.
3. Reynolds TB, Geller HM, Kuzma OT, Redeker AG. Spontaneous decrease in portal pressure with clinical improvement in cirrhosis. N Engl J Med 263:734-9, 1960.
4. Runyon BA. Care of patients with ascites. N Engl J Med 330:337-42, 1994.
5. Eisenmenger WJ, Ahrens EH, Blondheim SH, et al. The effect of rigid sodium restriction in patients with cirrhosis of the liver and ascites. J Lab Clin Med 34:1029-38, 1949.
6. Eisenmenger WJ, Blondheim SH, Bongiovanni AM, et al. Electrolyte studies on patients with cirrhosis of the liver. J Clin Invest 29:1491-9, 1950.
7. Runyon BA. Refractory ascites. Sem Liv Dis 13:343-51, 1993.
8. Runyon BA, Heck M. Utility of 24-hour urine sodium collections and urine Na/K ratios in the management of patients with cirrhosis and ascites. Hepatology 24:571 A (abstract), 1996.
9. Ho H, Zuckerman MJ, Ho TK, et al. Prevalence of associated infections in community-acquired spontaneous bacterial peritonitis. Am J Gastroenterol 91:735-42, 1996.
10. Kelton JG, Ulan R, Stiller C, Holmes E Comparison of chemical composition of peritoneal fluid and serum. Ann Intern Med 89 67-70, 1978.
11. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatrema in cirrhosis with ascites Dig Dis 21:249-55, 1976
12. Gauthier A, Levy VG, Quinton A, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomized study. Gut 27:705-9, 1986
13. Hampson NB. Smokeless is not saltless. N Engl J Med 312:919-20, 1985.
14. Mulhausen R, Eichenholz A, Blumentals A. Acid-base disturbances in patients with cirrhosis of the liver. Medicine 46:185-9, 1967.
15. Sterns RH. Severe symptomatic hyponatremia: treatment and outcome. Ann Intern Med 107:656-64, 1987.
16. Wezolek ZK, McComb RD, Pfeiffer RF, et al. Pontine and extrapontine myelmolysis following liver transplantation: relation to serum sodium. Transplantation 48:1006-12, 1989.
17. Bernardi M, Santini C, Trevisani F, et al Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 26:629-35, 1985.
18. Evans JM, Andrews KL, Chutka DS, et al. Pressure ulcers: prevention and management. Mayo Clin Proc 70:789-99, 1995.
19. Cohn JN. The management of chronic heart failure N Engl J Med 335:490-8, 1996.
20. Campra J, Reynolds TB. Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites. Dig Dis 23:1025-30, 1978.
21. Fogel MR, Sawhney VK, Neal EA, et al. Diuresis in the ascitic patient. a randomized controlled trial of three regimens. J Clin Gastroenterol 3(Suppl 1):73-80, 1981.
22. Sungaila I, Bartle WR, Walker SE, et al Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology 102:1680-5, 1992.
23. Perez-Ayuso RM, Arroyo V, Planas R, et al. Randomized comparative study of efficacy of furosemide vs. Spironolactone in nonazotemic cirrhosis with ascites. Gastroenterology 84:961-8, 1983.
24. Sawhney VK, Gregory PB, Swezey SE, et al. Furosemide disposition in cirrhotic patients. Gastroenterology 81:1012-16, 1981.
25. Daskalopoulos G, Laffi G, Morgan T, et al. Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. Gastroenterology 92:1859-63, 1987.
26. Arroyo V, Epstein M, Gallus G, et al. Refractory ascites in cirrhosis: mechanism and treatment. Gastroenterol Int 2:195-207, 1989
27. Stanley MM, Ochi S, Lee KK, et al Peritoneovenous shunting as compared with medical treatment in patients with alcoholic cirrhosis and massive ascites. N Engl J Med 321:1632-8, 1989
28. Klintmalm GB, Gonwa TA. Nephrotoxicity associated with cyclosporine and FK506. Liver Transplant Surg 1:11-19(Suppl 1), 1995
29. Madwar KR Comparison of single- and divided-dose therapy with Spironolactone (aldaclone) in benign essential hypertension. Curr Ther Res 27 190-6, 1980.
30. Angeli P, Pria MD, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 19:72-9, 1994.
31. Iber FL, Baum RA. Bumetanide in refractory ascites of cirrhosis of the liver: a comparison with furosemide. J Clin Pharmacol 21:697-700, 1981.
32. Gentilini P, Laffi G, LaVilla G, et al. Torasemide in the treatment of patients with cirrhosis and ascites. Cardiovasc Drugs Ther 7:81-5, 1993.
33. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema Gastroenterology 90:1827-33, 1986.
34. Guazzi M, Polese A, Magrini F, et al. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med 59:165-70, 1975.
35. Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients with tense cirrhotic ascites. Hepatology 20:825-8, 1994.
36. Kao HW, Rakov NE, Savage H, Reynolds TB. The effect of large volume paracentesis on plasma volume - a cause of hypovolemia? Hepatology 5:403-7, 1985.
37. Pinto PC, Amerian J, Reynolds TB Large-volume paracentesis in nonedematous patients with tense ascites: its effect on intravascular volume. Hepatology 8:207-10, 1988.
38. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites: results of a randomized study. Gastroenterology 93:234- 41, 1987.
39. Runyon BA, Antillon MR, Montano AA. Effect of diuresis versus therapeutic paracentesis on ascitic fluid opsonic activity and serum complement. Gastroenterology 97:158-62, 1989.
40. D'Amico G, Morabito A, Pagliaro L, et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31:468-75, 1986.
41. Bories P, Garcia-Compean D, Michel H, et al. The treatment of refractory ascites by the LeVeen shunt: a multi-center controlled trial (57 patients). J Hepatol 3:212-18, 1986.
42. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl Med 333:1190-5, 1995
43. Epstein M. Lifschutz M. Renal eicosanoids as determinants of renal function in liver disease. Hepatology 6:1359-67, 1987.
44. Mirouze D, Zipser RD. Reynolds TB Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 3:50-5, 1983.
45. de Ledinghen V, Mannant P-R, Foucher J, et al. Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. J Hepatol 24:570-3, 1996.
46. Arroyo V. Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23:164-76, 1996.
47. Strauss E, DeSa MDFG, Lacet CMC, et al. Standardization of a therapeutic approach for ascites due to chronic liver disease: a prospective study of 100 cases. Hepatology 7:409-11, 1987.
48. Gines P, Tito L, Arroyo V, et al. Randomized study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 94:1493-1502, 1988.
49. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111:1002-10, 1996.
50. Garcia-Compean D, Villarreal JZ, Cuevas HB, et al Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: a randomized controlled trial. Liver 13:233-8, 1993.
51. Rothschild M, Oratz M, Evans C, et al. Alterations in albumin metabolism after serum and albumin infusions. J Clin Invest 43:1874-80, 1964
52. Wilkinson P, Sherlock S. The effect of repeated albumin infusions in patients with cirrhosis. Lancet ii:1125-9, 1962.
53. Pietrangelo A, Panduro A, Chowdhury JR, et al Albumin gene expression Ls down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 89:1755-60, 1992.
54. Dykes PW A study of the effects of albumin infusion in patients with cirrhosis of the liver. Quart J Med 119:297-327, 1961.
55. Runyon BA, Montano AA, Akriviadis EA, et al. The serum-aseites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 117:215-20, 1992.
56. Moller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastreonterology 109:1917-25, 1995.
57. Bosch J, Arroyo V, Betriu A, et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 78:92-9, 1980.
58. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Gastroenterology 99:1736-44, 1990
59. Salerno F, Badalamenti S, Lorenzano E, et al. Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 13:707-13, 1991.
60. Cabrera J, Inglada L, Quintero E, et al. Large-volume paracentesis and intravenous saline: effects on the renin-angiotensin system. Hepatology 14:1025-8, 1991.
61. Vermeulen LC, Ratko TA, Erstad BL, et al. A paradigm for consensus, the University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med 155:373-9, 1995.
62. LeVeen HH, Christoudias G, Ip M, et al. Peritoneovenous shunting for ascites. Ann Surg 180:580-19, 1974.
63. Norfray JF, Henry HM, Givens JD, Sparberg MS. Abdominal complications from peritoneal shunts. Gastroenterology 77:337-40, 1979.
64. Gines P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting m cirrhosis with refractory ascites. N Engl J Med 325:829-35, 1991.
65. Stanley MM, Reyes CV, Grccnlcc HB, et al. Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites' an autopsy study with clinical considerations. Dig Dis Sci 41 571-7, 1996.
66. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites N Engl J Med 332:1192-7, 1995.
67. Somberg KA, Lake JR, Tomlanovich SJ, et al. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 21:709-16, 1995.
68. Lebrec D, Giuily N, Hadengue A, et al Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites' a randomized trial. J Hepatol 25 135-44, 1996.
69. Wong F, Sniderman K, Liu P, et al. Transjugular intrahepatic portosystemic stent-shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites Ann Intern Med 122:816-22, 1995.
70. Miller FG, Fins JJ. A proposal to restructure hospital care for dying patients. N Engl J Med 334:1740-2, 1996.
71. Baldus WP, Feichter RN, Summerskili WHJ. The kidney in cirrhosis: clinical and biochemical features of azotemia in hepatic failure. Ann Intern Med 60:353-77, 1964.
72. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver: clinical and pathological characteristics. Am J Med 39:184-98, 1965.